Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1619-7089
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review ; volume:45 ; number:3 ; day:16 ; month:12 ; year:2017 ; pages:496-508 ; date:3.2018
European journal of nuclear medicine and molecular imaging ; 45, Heft 3 (16.12.2017), 496-508, 3.2018
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Eyben, Finn Edler von
- Beteiligte Personen und Organisationen
-
Roviello, Giandomenico
Kiljunen, Timo
Uprimny, Christian
Virgolini, Irene
Kairemo, Kalevi
Joensuu, Timo
SpringerLink (Online service)
- DOI
-
10.1007/s00259-017-3895-x
- URN
-
urn:nbn:de:1111-201803256163
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Eyben, Finn Edler von
- Roviello, Giandomenico
- Kiljunen, Timo
- Uprimny, Christian
- Virgolini, Irene
- Kairemo, Kalevi
- Joensuu, Timo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy
Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Early biochemical and radiographic response after one cycle of [177Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)